resultFull

FOOT-AND-MOUTH DISEASE VIRUS A CAPSID, MOLECULAR MODEL

Foot-and-mouth disease virus A capsid complexed with antibody M688F. Molecular model of a foot-and-mouth disease (FMD) virus A capsid (pink tones) complexed with antibody M688F (green). (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

ZIKA VIRUS COMPLEXED WITH ANTIBODY, MOLECULAR MODEL

Zika virus ZIKV complexed with an antibody. Molecular model of the ZIKV envelope protein E (blue) complexed with the antibody rhMZ100-C (cyan, orange). (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

ZIKA VIRUS COMPLEXED WITH ANTIBODY, MOLECULAR MODEL

Zika virus ZIKV complexed with an antibody. Molecular model of the ZIKV envelope protein E (blue) complexed with the antibody rhMZ100-C (cyan, orange). (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

TILAPIA LAKE VIRUS POLYMERASE, MOLECULAR MODEL

Tilapia Lake Virus polymerase. Molecular model of Tilapia Lake Virus polymerase in cRNA pre-initiation state mode A. The image shows the cRNA in orange-green and cyan, the polymerase acidic protein in red, the putative PB1 polymerase subunit in blue and the RNA-dependent RNA polymerase in green. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

FOOT-AND-MOUTH DISEASE VIRUS A CAPSID, MOLECULAR MODEL

Foot-and-mouth disease virus A capsid complexed with antibody M688F. Molecular model of a foot-and-mouth disease (FMD) virus A capsid (pink tones) complexed with antibody M688F (green). (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

ZIKA VIRUS XRRNA1 MUTANT, MOLECULAR MODEL

Zika virus xrRNA1 mutant. Molecular model of the Xrn1 resistant mosquito-borne Zika virus RNA. This noncoding RNA produced by arthropod-borne flaviviruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

RESPIRATORY SYNCYTIAL VIRUS ASSEMBLY, MOLECULAR MODEL

Respiratory syncytial virus (RSV) A nucleocapsid-like assembly. Molecular model of a respiratory syncytial virus (RSV) A nucleocapsid-like assembly. The viral nucleoprotein is shown in cyan, the human RNA in orange. The nucleoprotein forms a helical assembly in order to encapsulate and protect the RNA genome from degradation. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

INFLUENZA A VIRUS, MOLECULAR MODEL

Influenza A virus helical ribonucleoprotein. Molecular model of the influenza A virus helical ribonucleoprotein capsid with the nucleoprotein shown in blue and the RNA in red. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

TILAPIA LAKE VIRUS POLYMERASE, MOLECULAR MODEL

Tilapia Lake Virus polymerase. Molecular model of Tilapia Lake Virus polymerase in cRNA pre-initiation state mode A. The image shows the cRNA in orange-green and cyan, the polymerase acidic protein in red, the putative PB1 polymerase subunit in blue and the RNA-dependent RNA polymerase in green. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

INFLUENZA A VIRUS, MOLECULAR MODEL

Influenza A virus helical ribonucleoprotein. Molecular model of the influenza A virus helical ribonucleoprotein capsid with the nucleoprotein shown in blue and the RNA in red. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

ZIKA VIRUS XRRNA1 MUTANT, MOLECULAR MODEL

Zika virus xrRNA1 mutant. Molecular model of the Xrn1 resistant mosquito-borne Zika virus RNA. This noncoding RNA produced by arthropod-borne flaviviruses inhibits the cellular exoribonuclease XRN1 and alters host mRNA stability. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

RESPIRATORY SYNCYTIAL VIRUS ASSEMBLY, MOLECULAR MODEL

Respiratory syncytial virus (RSV) A nucleocapsid-like assembly. Molecular model of a respiratory syncytial virus (RSV) A nucleocapsid-like assembly. The viral nucleoprotein is shown in cyan, the human RNA in orange. The nucleoprotein forms a helical assembly in order to encapsulate and protect the RNA genome from degradation. (KEYSTONE/SCIENCE PHOTO LIBRARY/LAGUNA DESIGN)

PAPIERPOSTBRIEF MIT METALLHAKEN AUF BLAUEM PASTELLFARBENEM HINTERGRUND, KONZEPT. PHISHING UND HACKER-ANGRIFF PER E-MAIL, KREATIVE IDEE. HACKER UND SPAM-MAILING. DATENDIEBSTAHL. FALLE UND TÄUSCHUNG

Papierpostbrief mit Metallhaken auf blauem pastellfarbenem Hintergrund, Konzept. Phishing und Hacker-Angriff per E-Mail, kreative Idee. Hacker und Spam-Mailing. Datendiebstahl. Falle und Täuschung (KEYSTONE/CHROMORANGE/Ales Utouka)

272194

Affiche contre le SIDA sur la route reliant My Tho à Hô Chi Minh-Ville (Viêtnam), 1994. (KEYSTONE/ROGER VIOLLET/FRAN"OISE DEMULDER)

VIETNAM - POSTS(SHOWS) AIDS

Affiche contre le SIDA sur la route reliant My Tho à Hô Chi Minh-Ville (Viêtnam), 1994. (KEYSTONE/ROGER VIOLLET/FRAN"OISE DEMULDER)

DJIBOUTI - AIDS - PREVENTION

Affiche de prévention contre le SIDA dans le centre-ville. Djibouti (République de Djibouti), 1990. (KEYSTONE/ROGER VIOLLET/FRAN"OISE DEMULDER)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Transparent 100000 Fachkraefte Haengen Hängen gelassen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Karl Lauterbach , Bundesgesundheitsminister SPD , und rechts Ricarda Piepenhagen Gruenderin von Nicht Genesen neben Protestler mit Schild Karl hoer zu Hör Wir brauchen Therapien und Praevention fuer Long Covid der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Karl Lauterbach , Bundesgesundheitsminister SPD , und rechts Ricarda Piepenhagen Gruenderin von Nicht Genesen neben Protestler mit Schild Karl hoer zu Hör Wir brauchen Therapien und Praevention fuer Long Covid der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Karl Lauterbach , Bundesgesundheitsminister SPD , und rechts Ricarda Piepenhagen Gruenderin von Nicht Genesen neben Protestler mit Schild Karl hoer zu Hör Wir brauchen Therapien und Praevention fuer Long Covid der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Karl Lauterbach , Bundesgesundheitsminister SPD , neben Protestler mit Schild Gesundheit ist kein Luxusgut Helft den Betroffenen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Weisser Kittel und Fotos Long Covid Betroffenen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Weisser Kittel und Fotos Long Covid Betroffenen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Transparent 100000 Fachkraefte Haengen Hängen gelassen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Weisser Kittel und Fotos Long Covid Betroffenen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

LONG COVID AWARENESS DAY

DEU, Deutschland, Germany, Berlin, 15.03.2024.Protestler mit Schild Gesundheit ist kein Luxusgut Helft den Betroffenen der Initiative #NichtGenesen gegen die Folgen von Covid Corona und der Forderung Wir forschen Forschung unter dem Motto Nicht Genesen Wir Leiden Wir Sterben Sie schauen Zu beim dritten Internationaler Long Covid Awareness Day vor dem vor dem Reichstag Sitz Deutcher Bundestag in Berlin Deutschland . Protest gegen das Leiden vieler Menschen von Long Covid und mehr biomedizinische Forschung um Post-Covid, ME/CFS und Post-Vac . Mit 500 Portraits von Menschen, die aufgrund der Spaetfolgen der Pandemie ihrem Beruf nicht mehr nachgehen koennen. (KEYSTONE/SUEDDEUTSCHE ZEITUNG PHOTO/Stefan Boness/IPON)

HOME COVID-19 TESTS

A box of home COVID-19 testing kits, in New York on Friday, March 8, 2024. (Â Richard B. Levine) Photo via Newscom (KEYSTONE/NEWSCOM/Richard B. Levine)

VESICULAR STOMATITIS VIRUS INFECTION, TEM

Transmission electron micrograph (TEM) showing vesicular stomatitis virus (VSV) particles (green) budding from infected cells (blue). VSV primarily infects horses, pigs and cattle, causing lesions to form in the mouth, tongue, lips, nostrils, and hooves. Discomfort due to these lesions can cause animals to refuse to eat, resulting in malnourishment. VSV can be transmitted to humans where it causes flu-like symptoms. Treatment typically involves antibiotics. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

VESICULAR STOMATITIS VIRUS INFECTION, TEM

Transmission electron micrograph (TEM) showing vesicular stomatitis virus (VSV) particles (orange) budding from infected cells (green). VSV primarily infects horses, pigs and cattle, causing lesions to form in the mouth, tongue, lips, nostrils, and hooves. Discomfort due to these lesions can cause animals to refuse to eat, resulting in malnourishment. VSV can be transmitted to humans where it causes flu-like symptoms. Treatment typically involves antibiotics. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

VESICULAR STOMATITIS VIRUS INFECTION, TEM

Transmission electron micrograph (TEM) showing vesicular stomatitis virus (VSV) particles (orange) budding from infected cells (blue). VSV primarily infects horses, pigs and cattle, causing lesions to form in the mouth, tongue, lips, nostrils, and hooves. Discomfort due to these lesions can cause animals to refuse to eat, resulting in malnourishment. VSV can be transmitted to humans where it causes flu-like symptoms. Treatment typically involves antibiotics. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

HERPES SIMPLEX VIRUS, TEM

Coloured transmission electron micrograph (TEM) of a herpes simplex virus (HSV) particle. This virus infects humans, causing herpes. Herpes is a common, chronic infection. It is mostly symptomless, but can cause ulceration of the skin, especially around the lips and genitals. Medication is available to reduce symptoms, but there is no cure. (KEYSTONE/SCIENCE PHOTO LIBRARY/NIAID)

TOPSHOT-BRAZIL-HEALTH-VIRUS-DENGUE

TOPSHOT - Actors dress up as Aedes aegypti mosquitoes to raise awareness among the population about the importance of keeping their homes and streets clean in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

View of a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A health worker checks potted plant dishes for outbreaks of the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

Actors dress up as Aedes aegypti mosquitoes to raise awareness among the population about the importance of keeping their homes and streets clean in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

Actors dress up as Aedes aegypti mosquitoes to raise awareness among the population about the importance of keeping their homes and streets clean in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

View of a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

View of a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A health worker vaccinates a child against Dengue at a health center in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

View of a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

View of a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A worker prepares a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

View of a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A health worker prepares to vaccinates a child against Dengue at a health center in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A health worker vaccinates a child against Dengue at a health center in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A worker prepares a drone used to map and drop larviciding capsules in water tanks and places that can accumulate water to fight the Aedes aegypti mosquito in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

BRAZIL-HEALTH-VIRUS-DENGUE

A health worker prepares to vaccinates a child against Dengue at a health center in Belo Horizonte, Minas Gerais state, Brazil on March 2, 2024. (Photo by Douglas MAGNO / AFP) (KEYSTONE/AFP/DOUGLAS MAGNO)

PUBLIC TRANSIT IN NEW YORK

Passengers on an NYCTA M79 SBS bus traveling crosstown in New York on Wednesday, February 28, 2024. (Â Richard B. Levine) Photo via Newscom (KEYSTONE/NEWSCOM/Richard B. Levine)

ANTIBODIES ATTACKING VIRUS PARTICLE, ILLUSTRATION

Illustration of a virus particle (round) surrounded by antibody, or immunoglobulin, molecules. The y-shaped antibody molecules have two arms that can bind to specific antigens, for instance viral proteins. In doing this they mark the antigen for destruction by phagocytes, white blood cells that ingest and destroy foreign bodies. Antibodies can also kill some pathogens directly and can neutralise toxins. (KEYSTONE/SCIENCE PHOTO LIBRARY/KEITH CHAMBERS)

ANTIBODIES ATTACKING VIRUS PARTICLES, ILLUSTRATION

Illustration of virus particles (round) surrounded by antibody, or immunoglobulin, molecules. The y-shaped antibody molecules have two arms that can bind to specific antigens, for instance viral proteins. In doing this they mark the antigen for destruction by phagocytes, white blood cells that ingest and destroy foreign bodies. Antibodies can also kill some pathogens directly and can neutralise toxins. (KEYSTONE/SCIENCE PHOTO LIBRARY/KEITH CHAMBERS)

ANTIBODIES ATTACKING VIRUS PARTICLE, ILLUSTRATION

Illustration of a virus particle (round) surrounded by antibody, or immunoglobulin, molecules. The y-shaped antibody molecules have two arms that can bind to specific antigens, for instance viral proteins. In doing this they mark the antigen for destruction by phagocytes, white blood cells that ingest and destroy foreign bodies. Antibodies can also kill some pathogens directly and can neutralise toxins. (KEYSTONE/SCIENCE PHOTO LIBRARY/KEITH CHAMBERS)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff works inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, Adar Poonawalla, Chief Executive Officer (CEO) at Serum Institute of India (SII), speaks during an interview with AFP at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, staff monitor control panels inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects vials of the R21 Malaria vaccine after its filling at the Serum Institute of India (SII) - the largest vaccine manufacturer in the world at the SII headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff arranges boxes of vials of the R21 Malaria Vaccine inside the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff prepares to manually check vials after disinfecting his protective gear inside the filling unit of the R21 Malaria Vaccine inside the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, vials of the R21 Malaria Vaccine are seen at the packing section of the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects a vial of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff monitors a control panel inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff packs vials of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, the Serum Institute of India (SII) logo is seen at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff works inside the Human Papillomavirus (HPV) vaccine manufacturing unit of the Serum Institute of India (SII) at its headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)

INDIA-HEALTH-VACCINES-MALARIA-AFRICA

In this photograph taken on February 27, 2024, a staff inspects a vial of the R21 Malaria Vaccine at the Serum Institute of India (SII) headquarters in Hadapsar, Pune. The world's biggest vaccine maker will start rolling out a cheap new malaria inoculation in Africa from May, bolstering the fight against one of the most deadly infectious diseases globally. The mosquito-borne malady currently kills more than 600,000 people a year, 95 percent of them in Africa, according to the World Health Organization (WHO). (Photo by Indranil MUKHERJEE / AFP) / TO GO WITH 'India-health-vaccines-malaria-Africa' FOCUS. (KEYSTONE/AFP/INDRANIL MUKHERJEE)